Results 161 to 170 of about 981,832 (295)

Scientific Meetings in Medical Oncology: Are We Facing a Time- and Resource-Consuming Plethora? [PDF]

Curr Oncol
Gebbia V, Piazza D, Scrima F, Passanisi A, Sambataro D, Scandurra G, Valerio MR.   +6 more
europepmc   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

European Society for Medical Oncology (ESMO) congress 2025. [PDF]

Lancet Reg Health Eur
Nedic I.
europepmc   +1 more source

Trainee Evaluations of Preparedness for Clinical Trials in Medical Oncology-A National Questionnaire. [PDF]

Curr Oncol, 2023
Febbraro M, Kazemi G, Juergens R, Pond GR.   +3 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Hypertriglyceridemia During Anticancer Therapy in Pediatric Patients with Acute Lymphoblastic Leukemia – A Nationwide Experience

Cancer Management and Research
Joanna Zawitkowska,1,2 Eryk Latoch,3,4 Katarzyna Karska,1 Katarzyna Drabko,1 Monika Lejman,5 Klaudia Ewelina Paczóska,6 Tomasz Ociepa,6 Anna Malecka,7 Dorota Sęga-Pondel,8 Krzysztof Kalwak,8 Katarzyna Konończuk,3 Julia Ko&lstrok ...
Zawitkowska J, Latoch E, Karska K, Drabko K, Lejman M, Paczóska KE, Ociepa T, Malecka A, Sęga-Pondel D, Kalwak K, Konończuk K, Kołodrubiec J, Trelińska J, Demidowicz E, Andrzejewska M, Derwich K, Zakrzewska Z, Skoczeń S, Mizia-Malarz A, Karolczyk G, Bal W, Chaber R, Tyszka P, Badowska W, Janiszewska M, Kowalczyk J, Młynarski W, Szczepański T, Styczyński J, Irga-Jaworska N, Muszyńska-Rosłan K   +30 more
doaj  

Nutritional Risk in Patients Admitted to Medical Oncology Departments: Prevalence, Associated Factors and Clinical Outcomes in a Multicentre Prospective Study. [PDF]

Nutrients
Teigell Muñoz FJ, Llobera Rius L, Medina Ortega L, Villacé Gallego P, Marco-Hernández J, Fernández Fernández EP, Esquerrà Molas A, Liesa Delgado L, Sáez Urán LM, González Olmedo J, Heredia-Mena C, Romero Hernández J, Llaberia-Torrelles M, Delgado Heredia MJ, Bazaga Rodas N, Fernández-Cordón L, Macía-Rodríguez C, Soldado J, García-Villa A.   +18 more
europepmc   +1 more source

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology

Biosimilars; Oncologia; PrescriptorsBiosimilares; Oncología; PrescriptoresBiosimilars; Oncology; PrescribersBackground: Biosimilars can potentially improve the sustainability of cancer care; however, uptake is sometimes limited by safety concerns and a ...
Vyas, Malvika, Cardoso, Fatima, Giuliani, Rosa, Tabernero Caturla, Josep, McGregor, Keith Hanson, de Vries, Elisabeth G E   +5 more
core  

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Medical Oncology [PDF]

, 2020
Ravin Ratan, Shreyaskumar R. Patel
openaire   +2 more sources